This study investigates pancreatic ductal adenocarcinoma. It explores the role of genetic information and proteins from tumors in understanding treatment responses.
The study evaluates whether genetic test results can provide insights into tumor response and resistance to treatment. It looks at the feasibility of obtaining these results in a timely manner to inform treatment decisions.
- Who can participate: Participants must be 18 years or older with a diagnosis of resectable or locally advanced pancreatic ductal adenocarcinoma and be medically fit for surgery.
- Study details: Participants will receive standard chemotherapy and provide samples for genetic testing. They will visit the clinic regularly and complete questionnaires.
- Study visits: The study requires visits every 4 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand